XM does not provide services to residents of the United States of America.

Indian shares inch lower as US election uncertainty looms



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>INDIA STOCKS-Indian shares inch lower as US election uncertainty looms</title></head><body>

Updates at 10:26 a.m. IST

By Bharath Rajeswaran

Nov 5 (Reuters) -Indian shares inched lower on Tuesday as investors avoided making big bets ahead ofthe U.S. presidential election and lacklustreearnings and sustained foreign outflows continued to weighon sentiment.

The NSE Nifty 50 .NSEI was down 0.11% at 23,973 points as of 10:26 a.m. IST, while the BSE Sensex .BSESN lost 0.13%to 78,699.5.

Both benchmarks fell about 1.25% each on Monday, their biggest single-day loss since Oct. 3.

Democrat Kamala Harris and Republican Donald Trump remain virtually tied in opinion polls ahead of Tuesday's U.S. election. The winner will likely not be known for days after voting ends.

A Trump win could lead to lower corporate tax rates in the U.S., which is expected to boost spending and, in turn, benefitseveral equity sectors in India, while a Harris victory is seen as a sign of policy continuity, a neutral-to-mildly-positive outcome for Indian stocks, according to analysts.

With Indian markets already trading at elevated valuations, uncertainty over the U.S. elections has served as a key catalyst for the ongoing correction, said Vinit Bolinjkar, head of research at Ventura Securities.

Lacklustre earnings and sustained foreign selling have also weighedon domestic equities over the last five weeks, with theNifty 50 dropping 8.7% from record highs hiton Sept. 27.

Eight of the 13 major sectors declined on the day. The broader, more domestically focused small- .NIFSMCP100 and mid-caps .NIFMDCP100 dropped about 0.4%each.

Among individual stocks, Amara Raja Energy and Mobility AMAR.NS fell 4.2%after posting its slowest profit growth in a year in the Septemberquarter.

Gland Pharma GLAD.NS rose 10%, on course for its biggest single-daygain in 15 months, lifting the pharma index .NIPHARM 0.4%.

While the generic injectables maker posted a profit drop, its overallprofit margin was better-than-expected due to its diverse segmental mix, said Motilal Oswal Financial Services, which forecastan earnings recovery for the company infiscal year 2025-2027.

($1 = 84.1360 Indian rupees)



Reporting by Bharath Rajeswaran in Bengaluru; Editing by Sumana Nandy, Janane Venkatraman and Sonia Cheema

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.